# Avacta Group and LG Chem Life Sciences additional drug development programmes in expanded partnership

- Link: https://www.directorstalkinterviews.com/avacta-group-and-lg-chem-life-sciences-additional-drug-development-programmes-in-expanded-partnership/412852143
- Published: 2020-08-18T07:30:27+01:00
- Author: Giles Arbor

**[Avacta](https://www.directorstalkinterviews.com/company/avacta-group-plc/avct.l)
Group plc** ([LON:AVCT](https://www.directorstalkinterviews.com/ftse-company/avacta-group-plc/avct.l)),
the developer of Affimer^(®) biotherapeutics and reagents, has announced the expansion
of its existing multi-target collaboration and development agreement with LG Chem
Life Sciences, the life sciences division of the South Korean LG Group, to include
new programmes incorporating Avacta’s Affimer XT^(TM) serum half-life extension 
system.

In December 2018, Avacta and LG Chem entered into a multi-target therapeutics development
agreement to develop Affimer^(®) therapeutics in several disease areas potentially
worth over $300m to Avacta. The companies have today agreed to expand this drug 
development partnership to include Avacta’s Affimer XT^(TM) technology, which can
be used to control the time a drug spends in the circulation.

The expansion of the partnership includes an undisclosed additional upfront payment,
plus near-term pre-clinical milestones and longer-term clinical development milestones
totaling $98.5m for two therapeutics to be developed using the Affimer XT technology.
Under the terms of the extended agreement, LG Chem has the exclusive rights to develop
and commercialise, on a world-wide basis, Avacta’s Affimer PD-L1 inhibitor with 
Affimer XT serum half-life extension.

The expanded partnership also provides LG Chem with rights to develop and commercialise
other Affimer and non-Affimer biotherapeutics combined with Affimer XT half-life
extension for a range of indications and Avacta could earn up to $55m in milestone
payments for each of these new products. 

In addition, under the agreement Avacta will earn royalties on all future Affimer
XT product sales by LG Chem.

> **Dr. Alastair Smith, Chief Executive of Avacta Group commented:**
> “I am delighted with this expansion to the agreement with LG Chem, with whom we
> have developed a strong collaborative partnership. LG Chem is a world-class drug
> development partner with excellent biologics manufacturing and clinical development
> capabilities and a pioneering vision to develop innovative therapies.
> The expansion of our collaboration to develop new therapies for patients with 
> cancer and other diseases is another strong validation of the Affimer technology
> and its potential as a therapeutic platform to deliver a pipeline of new drugs.
> We look forward to developing these new therapies with our partners, LG Chem, 
> and I look forward to updating the market on this and our other drug development
> and diagnostics progammes in due course.”

Share on:
